PROS1 and posterior cortical atrophy: Enzalutamide-treated CR-PCa patients who were PSA-negative or ARV7-low and PSA-positive had median overall survival of 29.4 and 20.4 months, respectively, whereas ARV7-high and PSA-positive patients had significantly decreased overall survival at 12.5 months [87].